Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Long-Term Investments (2022 - 2025)

Historic Long-Term Investments for Century Therapeutics (IPSC) over the last 4 years, with Q2 2025 value amounting to $2.7 million.

  • Century Therapeutics' Long-Term Investments fell 9632.64% to $2.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $2.7 million, marking a year-over-year decrease of 9632.64%. This contributed to the annual value of $30.8 million for FY2024, which is 6541.03% down from last year.
  • According to the latest figures from Q2 2025, Century Therapeutics' Long-Term Investments is $2.7 million, which was down 9632.64% from $20.7 million recorded in Q1 2025.
  • In the past 5 years, Century Therapeutics' Long-Term Investments registered a high of $144.6 million during Q2 2023, and its lowest value of $2.7 million during Q2 2025.
  • Moreover, its 4-year median value for Long-Term Investments was $54.9 million (2022), whereas its average is $65.1 million.
  • Per our database at Business Quant, Century Therapeutics' Long-Term Investments skyrocketed by 19107.46% in 2023 and then tumbled by 9632.64% in 2025.
  • Quarter analysis of 4 years shows Century Therapeutics' Long-Term Investments stood at $51.9 million in 2022, then surged by 71.82% to $89.1 million in 2023, then plummeted by 65.41% to $30.8 million in 2024, then plummeted by 91.27% to $2.7 million in 2025.
  • Its Long-Term Investments was $2.7 million in Q2 2025, compared to $20.7 million in Q1 2025 and $30.8 million in Q4 2024.